Investigation into the impact of renal denervation on microvascular function in uncontrolled hypertension: a prospective observational study.

Investigation into the impact of renal denervation on microvascular function in uncontrolled hypertension: a prospective observational study. - Microvascular Insight From Renal Denervation (MIND-RND)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040553

Enrollment

Registered

2026-06-30

Start date

2026-06-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I10.90

Interventions

Group 1: Interventional renal denervation (one-time)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Uncontrolled arterial hypertension with a clinical indication for renal denervation Optional: MRI compatibility (no tinnitus, no tattoos, no magnetic implants)

Exclusion criteria

Exclusion criteria: 1. Clinically significant and uncontrolled supraventricular or ventricular cardiac arrhythmias (excluding adequately rate-controlled atrial fibrillation) 2. Severe valvular heart disease and/or valvular disease requiring intervention 3. History of significant neurological or psychiatric disorders (e.g., seizure disorders, severe traumatic brain injury, depression, schizophrenia, dementia) 4. Malignancies limiting life expectancy 5. Intolerance to ASA (acetylsalicylic acid) 6. Impaired renal function (GFR <40 ml/min/1.73 m²) 7. Renal artery stenosis 8. Untreated secondary causes of hypertension 9. Severe aortic atherosclerosis

Design outcomes

Primary

Measure	Time frame
•Impact of renal denervation on microvascular function (retinal vascular function, PWV, FMD; pre and post) •Temporal dynamics of the effects of renal denervation on home blood pressure (remote telemonitoring over 12 months)	—

Secondary

Measure	Time frame
• Cardiovascular fitness (VO2max, grip strength, muscle mass) • Cardiovascular risk profile (composite score: blood pressure, lipid levels, physical activity, obesity) • Clinical parameters for vascular function (e.g. arterial stiffness) • Clinical parameters for cardiac function (e.g., LVEF, diastolic function) • Microvascular function (MRI: STRIVE score) • Cognition (composite cognition score) • Blood parameters (inflammation, BDNF, Klotho, dementia markers, etc.) • Lifestyle factors • Frequency/severity of AEs and SAEs	—

Measure

Time frame

• Cardiovascular fitness (VO2max, grip strength, muscle mass) • Cardiovascular risk profile (composite score: blood pressure, lipid levels, physical activity, obesity) • Clinical parameters for vascular function (e.g. arterial stiffness) • Clinical parameters for cardiac function (e.g., LVEF, diastolic function) • Microvascular function (MRI: STRIVE score) • Cognition (composite cognition score) • Blood parameters (inflammation, BDNF, Klotho, dementia markers, etc.) • Lifestyle factors • Frequency/severity of AEs and SAEs

—

Countries

Germany

Contacts

Public ContactLading Yves

Uniklinik Magdeburg

yves.lading@med.ovgu.de49 3916724860

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026